| Title | Long term results of patients with malignant carcinoid syndrome receiving octreotide LAR. | | Author(s) | Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME | | Institution | Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK. | | Source | Aliment Pharmacol Ther 2009 Jul 2. | | Abstract | Aim: To present long-terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome.
Methods: 108 patients with metastatic midgut neuroendocrine tumours were included. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria. Adverse effects were reported.
Results: 26/108 (24%) patients had a sustained symptomatic response (with no evidence of radiological progression) to octreotide LAR (median follow-up :19 months). In the remaining patients, loss of symptomatic response with the initial dose was noted within 3-60 months (median time:12 months). In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment. Overall, in 45.3% (49/108) of patients (median follow-up: 25 months, range: 3-72 months), symptoms were well controlled during the study period only with octreotide LAR, and no additional treatment was required. No significant adverse effects were noted.
Conclusions: Octreotide LAR treatment provides a sustained symptomatic response in half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19573169 |
|
